Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 229-238, 2009. First published December 18, 2008; 10.1373/clinchem.2008.108886
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2008.108886v1
55/2/229    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Devaraj, S.
Right arrow Articles by Jialal, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Devaraj, S.
Right arrow Articles by Jialal, I.
(Clinical Chemistry. 2009;55:229-238.)
© 2009 American Association for Clinical Chemistry, Inc.

Reviews

The Evolving Role of C-Reactive Protein in Atherothrombosis

Sridevi Devaraj1, Uma Singh1 and Ishwarlal Jialal1,a

1 Laboratory for Atherosclerosis and Metabolic Research, University of California–Davis Medical Center, Sacramento, CA.

aAddress correspondence to this author at: 4635 Second Ave., Res. 1 Bldg., Rm. 3000, Sacramento, CA 95817. Fax 916-734-6593; e-mail ishwarlal.jialal{at}ucdmc.ucdavis.edu.

Background: Inflammation is pivotal in all phases of atherosclerosis. Among the numerous inflammatory biomarkers, the largest amount of published data supports a role for C-reactive protein (CRP) as a robust and independent risk marker in the prediction of primary and secondary adverse cardiovascular events. In addition to being a risk marker, there is much evidence indicating that CRP may indeed participate in atherogenesis.

Content: In this review, we focus on the role of CRP in promoting atherothrombosis by discussing its effects on endothelial cells, endothelial progenitor cells, monocyte-macrophages, and smooth muscle cells.

Conclusions: CRP is clearly a risk marker for cardiovascular disease and is recommended for use in primary prevention. In addition, CRP appears also to contribute to atherogenesis. However, much further research is needed, especially in appropriate animal models, to confirm the possible role of CRP in promoting atherothrombosis.




The following articles in journals at HighWire Press have cited this article:


Home page
 CirculationHome page
T. Koike, S. Kitajima, Y. Yu, K. Nishijima, J. Zhang, Y. Ozaki, M. Morimoto, T. Watanabe, S. Bhakdi, Y. Asada, et al.
Human C-Reactive Protein Does Not Promote Atherosclerosis in Transgenic Rabbits
Circulation, November 24, 2009; 120(21): 2088 - 2094.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.